Companies: 10,795·Total market cap: $144.5T
BioLineRx Ltd.

BioLineRx Ltd.

BLRXNASDAQHealthcare● Active
$3.07
$-0.16(-4.95%)
Market Cap$13358666
P/E Ratio—
52W High$6.59
52W Low$2.15
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

BioLineRx Ltd. (BLRX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BLRX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.12blrx eps ttm · blrx earnings per shareEarnings history
PE Ratio (TTM)—blrx pe ratio ttm · blrx price to earningsPE Ratio deep dive
Revenue (TTM)$1.4Mblrx revenue ttm · blrx annual revenueFull revenue history
Dividend YieldNo Dividenddoes blrx pay dividends · blrx dividend yieldDividend history
Shares Outstanding4.1Mblrx shares outstanding · blrx floatShares outstanding history
Next EarningsAug 13, 2026Est.blrx earnings date · blrx next earningsEarnings history

Explore BioLineRx Ltd. Data

blrx stock data · financials
Market Cap$13.4Mblrx market cap · blrx valuation
Analyst Forecast$— · Buy
DividendsNo Dividenddoes biolinerx ltd. pay dividends · blrx dividend yield
Revenue$1.2M-95.89%biolinerx ltd. annual revenue · blrx revenue
EarningsEPS $-0.29-141.67%blrx earnings · blrx eps
PE Ratio—blrx pe ratio · blrx price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$1.2M▼ 95.89% YoY
202320242025
biolinerx ltd. revenue · blrx revenue 2025
FY 2025Net Income-$1.2M▲ +87.16% YoY
202320242025
biolinerx ltd. net income · blrx profit 2025
FY 2025EPS$-0.29▼ 141.67% YoY
202320242025
blrx eps · biolinerx ltd. earnings per share 2025
TTM:Revenue: $1.4MNet Income: -$8.9MEPS: $-2.12View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy7 analystsis blrx a buy · blrx analyst rating
Strong Buy
0
Buy
7
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$3.07Current
$—Avg Target
$—High
blrx price target · blrx 12 month forecast

Total: 7 · Buy rate: 100.0%

Stock Performance

Full History
1D-4.95%
1W-9.17%
1M+0.00%
3M+15.85%
YTD+10.83%
1Y-48.23%
5Y-97.31%

About BioLineRx Ltd.

CEOPhilip A. Serlin
IPO DateJul 27, 2011
Employees28
CountryIL
Websitebiolinerx.com

BioLineRx Ltd. a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatmen…

BiotechnologyHealthcareNASDAQADRIL

what is biolinerx ltd. · blrx stock overview · biolinerx ltd. company profile · who is biolinerx ltd. ceo · blrx NASDAQ · biolinerx ltd. headquarters · biolinerx ltd. business segments

About Stock Overview & Key Data

BioLineRx Ltd. (BLRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 27, 2011. As of the latest trading session, BLRX stock price is $3.07, with a market capitalization of $13.4M. The stock has returned -48.23% over the past 12 months and +10.83% year-to-date.

According to 7 Wall Street analysts, the consensus rating for BioLineRx Ltd. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, BioLineRx Ltd. reported revenue of $1.2M and net income of -$1.2M. For detailed data — including BioLineRx Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, BioLineRx Ltd. (BLRX) stock price is $3.07. The stock is traded on NASDAQ under the ticker symbol BLRX. The 52-week range is $2.15 – $6.59.

BLRX stock priceBLRX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice